However, these studies reported that using MRAs can increase the risk of hyperkalemia in both groups; similarly, Desai et al. reported that the use of MRAs also increases the risk of hyperkalemia, especially in patients with compromised renal function or those concurrently taking other renin–angiotensin system inhibitors [59]. This evidence concerns the gene REN and Hyperkalemia.